Phenyl-3,4-dihydroisoquinolin-2(1H)-yl-ethan-1-one derivatives as dopamine D1 receptor positive allosteric modulators
Patent Information
- Application Number
- JP2023521348
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-10-07
- Filing Date
- 2021-10-05
- Publication Date
- 2024-11-27
- Estimated Expiration
- 2041-10-05
Smart Images

Figure 0007591138000001 
Figure 0007591138000002 
Figure 0007591138000003
Abstract
Description
[Technical field]
[0001] The present invention provides certain phenyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one related compounds, pharmaceutical compositions thereof, and methods for their use in the treatment of dopaminergic CNS disorders, including Parkinson's disease, Alzheimer's disease, schizophrenia, and attention deficit hyperactivity disorder (ADHD). [Background technology]
[0002] Many of the drugs currently in use act directly or indirectly through dopamine receptors. These include dopamine agonists and the dopamine precursor L-DOPA for Parkinson's disease, dopamine-releasing drugs for attention deficit disorder and narcolepsy, and dopamine reuptake inhibitors for depression. D1 receptors play an important role in motor activity and reward systems, and have a special role in maintaining higher cognitive functions for working memory, attention, and executive function (Arnsten AF, Cereb. Cortex (2013) 123, 2269-2281). Attempts to develop D1 agonists for clinical use have so far been unsuccessful, spurring the search for alternative approaches to increase D1 receptor activity.
[0003] One such approach is to identify allosteric enhancers (also known as positive allosteric modulators or PAMs) of the dopamine D1 receptor. (See Svensson K, et al., J. Pharmacol. Exp. Ther. (2017) 360:117-128). Allosteric modulators are drugs that enhance (positive allosteric modulators, or PAMs) or inhibit (negative allosteric modulators, or NAMs) the effect of the natural ligand by binding to a site (allosteric binding site) that is distinct from the orthosteric binding site of the receptor. By increasing the affinity of dopamine for the D1 receptor, D1 enhancers may amplify the response to endogenous dopamine and increase D1 tone in terms of when and where dopamine is released. This mode of action is in contrast to D1 agonists, which activate all accessible D1 receptors as long as they are present. In animal models of cognitive and locomotor activity, D1 agonists show a bell-shaped dose-response relationship, which is probably due to overstimulation at high doses. Some D1 agonists also show rapid development of tolerance because D1 receptors are constantly activated. In contrast, D1 potentiators rely on endogenous tone and are subject to normal feedback control, which may make them much less prone to overstimulation. Given the involvement of dopamine and D1 receptor signaling in these central nervous system functions, D1 potentiators that can increase D1 receptor activity may provide alternative and / or improved drugs for the treatment of certain dopamine-related disorders.
[0004] Parkinson's disease is a chronic, progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the brain. Parkinson's disease manifests with resting tremor along with other motor (e.g., bradykinesia and postural instability) and non-motor (e.g., cognitive impairment, sleep disorders, and depression) symptoms. Current therapies for the treatment of Parkinson's disease include the administration of non-selective dopamine precursors, such as levodopa, and dopamine receptor agonists. Direct-acting dopamine receptor agonist therapy may also be associated with impulse control disorders, psychosis, and cognitive deterioration due to its relatively high affinity for D2 receptors. Schizophrenia is a debilitating disease with complex pathological mechanisms. A component of schizophrenia is cognitive impairment, which may be associated with a lack of D1 receptor activation or D1 receptor downregulation. It has been hypothesized that D1 activation may be more selective than D2 regulation in treating cognitive impairment associated with schizophrenia. Alzheimer's disease is a chronic, progressive neurodegenerative disorder characterized by the loss of neurons and synapses in the cerebral cortex and certain subcortical regions. The progression of the disease includes cognitive impairments that are hypothesized to be due, at least in part, to reduced activation of D1 receptors, and thus activation of D1 may provide therapeutic benefits for the treatment of cognitive impairments associated with Alzheimer's disease. ADHD is a neurodevelopmental disorder characterized by problems with concentration, hyperactivity, or difficulty controlling speech and behavior appropriately for age. It is hypothesized that activation of D1 may provide therapeutic benefits for the treatment of ADHD. Thus, there remains a significant unmet need for safe and effective treatments for cognitive impairments or other neurological disorders associated with schizophrenia, Parkinson's disease, Alzheimer's disease, and / or ADHD, such as alternative and / or improved dopamine D1 receptor positive allosteric modulators (D1 PAMs).
[0005] WO2014 / 193781 lists certain 3,4-dihydroisoquinolin-2(1H)-yl compounds as D1 PAMs for the treatment of cognitive disorders associated with Parkinson's disease, Alzheimer's disease, schizophrenia, depression, or ADHD. Summary of the Invention
[0006] The present invention provides certain novel compounds that are selective PAMs of dopamine 1 receptor (D1), and demonstrate a beneficial combination of pharmacological properties, such as enhancing human D1 receptor signaling in response to dopamine, high oral in vivo availability, and in vivo efficacy in locomotor activation in habituated animals.As such, the compounds of the present invention are believed to be useful for treating Parkinson's disease, Alzheimer's disease, schizophrenia, and / or ADHD.The compounds of the present invention may provide an alternative treatment for such disorders.
[0007] The present invention relates to a compound of formula I, [ka] During the ceremony, R 1 but, [ka] and R 2 is -F or -Cl, R 3 is -F or -Cl, R 4 is -H or -F, However, R 1 but [ka] When R4 is -F,
[0008] The compounds of formula I are particularly useful in the treatment methods of the present invention, although certain configurations are preferred. The following paragraphs describe such preferred configurations. The present invention represented by formula I contemplates all individual enantiomers and diastereomers, as well as mixtures of enantiomers and / or diastereomers of the compounds, including racemates, although compounds having the absolute configurations described below are preferred. It is understood that these preferences are applicable to the treatment methods and novel compounds of the present invention.
[0009] A particular embodiment of formula I is a compound of formula Ia: [ka] During the ceremony, R 1 but, [ka] and R 2 is -F or -Cl, R 3 is -F or -Cl, R 4 is -H or -F, However, R 1 but [ka] When R4 is -F.
[0010] A particular embodiment of formula I is a compound of formula Ib: [ka] In the free base form, it can also be referred to as 2-(2-chloro-6-fluoro-phenyl)-1-[(1S,3R)-6-fluoro-3-(hydroxymethyl)-5-(3-hydroxy-3-methyl-butyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone.
[0011] The present invention further provides pharmaceutical compositions comprising a compound of Formula I, Ia, and / or Ib and a pharma- ceutically acceptable carrier, diluent, or excipient.
[0012] The following particular embodiments are compounds of formula I or Ia.
[0013] The present invention relates to [ka] The present invention provides a compound,
[0014] The present invention relates to [ka] The present invention provides a compound,
[0015] The present invention relates to [ka] The present invention provides a compound,
[0016] The present invention relates to [ka] The present invention provides a compound,
[0017] The present invention relates to [ka] The present invention provides a compound,
[0018] The present invention relates to [ka] The present invention provides a compound,
[0019] The present invention relates to [ka] The present invention provides a compound,
[0020] The present invention relates to [ka] The present invention provides a compound,
[0021] The present invention relates to [ka] The present invention provides a compound,
[0022] The present invention relates to [ka] The present invention provides a compound,
[0023] Additionally, the present invention provides a compound of one of the specific embodiments in the immediately preceding list, and a pharma- ceutically acceptable carrier, diluent, or excipient. For example, cocrystals are contemplated for the compound embodiments described herein.
[0024] The compounds of the present invention are selective PAMs of the dopamine 1 (D1) receptor with minimal activity at the dopamine 2 (D2) receptor. The compounds of the present invention may further provide their therapeutic benefits while avoiding the risk of drug-drug interactions. As such, the compounds of the present invention are believed to be useful in treating conditions where reduced D1 activity plays a role and D2 activation is undesirable, such as Parkinson's disease and schizophrenia, including alleviating certain associated symptoms, such as motor symptoms and cognitive impairments associated with Parkinson's disease and cognitive impairments and negative symptoms associated with schizophrenia, for example, mild cognitive impairment or dementia. The compounds of the present invention are also believed to be useful in improving motor symptoms of Parkinson's disease, either as a monotherapy or in combination with other therapies. The compounds of the present invention are also believed to be useful in treating certain symptoms of Alzheimer's disease, such as cognitive impairment, for example, mild cognitive impairment. Furthermore, the compounds of the present invention are believed to be useful in treating certain symptoms of ADHD. The compounds of the invention are also believed to be useful in treating dopaminergic CNS disorders including Parkinson's disease, Alzheimer's disease, dementia with Lewy bodies (LBD), vascular dementia, schizophrenia, ADHD, depression, autism, chronic musculoskeletal pain, fibromyalgia, cognitive dysfunction, sleep disorders, excessive daytime sleepiness, narcolepsy, shift work disorder, traumatic brain injury, chronic traumatic encephalopathy, obesity and appetite regulation, mood disorders, lethargy, apathy, and addictive disorders.
[0025] The present invention further provides a compound of formula I for use in therapy.The present invention further provides a compound of formula Ia for use in therapy.The present invention further provides a compound of formula Ib for use in therapy.
[0026] In another aspect, the invention provides a pharmaceutical composition comprising a compound of formula I, Ia, or Ib and one or more pharma- ceutically acceptable carriers, diluents, or excipients. This aspect of the invention further provides a pharmaceutical composition for treating Parkinson's disease, e.g., cognitive impairment associated with Parkinson's disease, comprising a compound of formula I, Ia, or Ib and one or more pharma- ceutically acceptable excipients, carriers, or diluents. In another embodiment of this aspect of the invention, a pharmaceutical composition for alleviating movement disorders associated with Parkinson's disease, comprising a compound of formula I, Ia, or Ib and one or more pharma- ceutically acceptable excipients, carriers, or diluents, is provided.
[0027] In another embodiment of this aspect of the invention, there is provided a pharmaceutical composition for treating Alzheimer's disease, e.g., alleviating cognitive impairment associated with Alzheimer's disease, comprising a compound of Formula I, Ia, or Ib and one or more pharma- ceutically acceptable excipients, carriers, or diluents.
[0028] Another embodiment of this aspect of the invention provides a pharmaceutical composition for treating schizophrenia, e.g., alleviating cognitive impairment associated with schizophrenia, comprising a compound of Formula I, Ia, or Ib and one or more pharma- ceutically acceptable excipients, carriers, or diluents.
[0029] Another embodiment of the present invention provides a pharmaceutical composition for treating ADHD, comprising a compound of Formula I, Ia, or Ib and one or more pharma- ceutically acceptable excipients, carriers, or diluents.
[0030] The invention further provides a method for treating Parkinson's disease, e.g., cognitive impairment associated with Parkinson's disease, or alleviating movement disorders, e.g., associated with Parkinson's disease, comprising administering to a patient in need of such treatment or alleviation an effective amount of a compound of Formula I, Ia, or Ib.
[0031] The invention further provides a method for treating Alzheimer's disease, e.g., cognitive impairment associated with Alzheimer's disease, comprising administering to a patient in need of such treatment an effective amount of a compound of Formula I, Ia, or Ib.
[0032] The invention further provides a method for treating schizophrenia, e.g., cognitive impairment associated with schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a compound of Formula I, Ia, or Ib.
[0033] The present invention further provides a method of treating ADHD, comprising administering to a patient in need of such treatment an effective amount of a compound of Formula I, Ia, or Ib.
[0034] In one embodiment of this aspect, the invention provides a compound of formula I, Ia, or Ib for use in treating Parkinson's disease. In one particular embodiment, the invention provides a compound of formula I, Ia, or Ib for use in treating cognitive impairment associated with Parkinson's disease. In another particular embodiment, the invention provides a compound of formula I, Ia, or Ib for use in alleviating movement disorders associated with Parkinson's disease.
[0035] The present invention further provides compounds of Formula I, Ia, or Ib for use in the treatment of schizophrenia, for example, for the treatment of cognitive impairment associated with schizophrenia.
[0036] The present invention further provides a compound of Formula I, Ia, or Ib for use in the treatment of ADHD.
[0037] The present invention further provides compounds of Formula I, Ia, or Ib for use in the treatment of Alzheimer's disease, for example, in the treatment of cognitive impairment associated with Alzheimer's disease.
[0038] In yet another aspect, the invention provides the use of a compound of Formula I, Ia, or Ib in the manufacture of a medicament for the treatment of Parkinson's disease, e.g., treating cognitive impairment associated with Parkinson's disease, or alleviating movement disorders associated with Parkinson's disease.
[0039] The invention further provides the use of a compound of Formula I, Ia, or Ib in the manufacture of a medicament for the treatment of schizophrenia, for example, for the treatment of cognitive impairment associated with schizophrenia.
[0040] The invention further provides the use of a compound of Formula I, Ia, or Ib in the manufacture of a medicament for the treatment of Alzheimer's disease, such as for the treatment of cognitive impairment associated with Alzheimer's disease.
[0041] The invention further provides the use of a compound of Formula I, Ia, or Ib in the manufacture of a medicament for the treatment of ADHD.
[0042] Although it is possible for the compound used in the method of the present invention to be directly administered without formulation, the compound is usually administered in the form of a pharmaceutical composition comprising a compound of formula I, Ia, or Ib as an active ingredient and at least one pharma- ceutically acceptable carrier, diluent, and / or excipient. These compositions can be administered by various routes, including oral, sublingual, nasal, subcutaneous, intravenous, and intramuscular. Such pharmaceutical compositions and the processes for preparing them are well known in the art. For example, see Remington: The Science and Practice of Pharmacy (University of the Sciences in Philadelphia, ed., 21st ed., Lippincott Williams & Wilkins Co., 2005).
[0043] The composition is preferably formulated in a unit dosage form, each dosage containing about 0.5 to about 800 mg of active ingredient. The term "unit dosage form" refers to a physically discrete unit suitable as a unitary dosage for human subjects and other mammals, each unit containing a predetermined amount of active material calculated to produce a desired therapeutic effect, in association with at least one suitable pharma- ceutically acceptable carrier, diluent, and / or excipient. It will be understood that the amount of compound actually administered will be determined by the physician in light of the relevant circumstances, including the condition being treated, the route of administration selected, the actual compound being administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms. The compounds of the present invention, for example, in the pharmaceutical compositions of the present invention, are contemplated to be used by chronic administration to treat Alzheimer's disease, Parkinson's disease, and / or schizophrenia, for example, to treat mild cognitive impairment associated with these diseases.
[0044] The dosage regimen of the present invention may be used in combination with other drugs used to treat / prevent / suppress or improve dopaminergic CNS disorders. Such other drug(s) may be administered by a route and in an amount commonly used, thus simultaneously or sequentially with LY3154207. For example, other active ingredients effective in treating Parkinson's disease that may be combined with the compounds of the present invention include, but are not limited to, (a) dopamine precursors such as levodopa, merevodopa, and etilevodopa; (b) dopamine agonists, including pramipexole, ropinirole, apomorphine, rotigotine, bromocriptine, cabergoline, and pergolide; (c) monoamine oxidase inhibitors, including selegiline and rasagiline; (d) COMT inhibitors, including tolcapone and entacapone; (e) acetylcholinesterase inhibitors, including rivastigmine and donepezil; and (f) antidepressants, including sertraline, citalopram, mirtazapine, and trazodone. Additionally, for example, other active ingredients effective in treating Alzheimer's disease that may be combined with the compounds of the present invention include, but are not limited to, acetylcholinesterase inhibitors, including rivastigmine and donepezil, NMDA antagonists, including memantine, certain antipsychotics, including risperidone, quetiapine, aripiprazole, olanzapine, and pimavanserin, and antidepressants, including sertraline, citalopram, mirtazapine, and trazodone.
[0045] As used herein, the term "patient" refers to a mammal, e.g., a human, in need of treatment for a disorder or disease. Humans are the preferred patients. As used herein, the patients treated by the compounds of the present invention suffer from dopaminergic CNS disorders, and as such share etiological aspects in that impaired dopamine signaling is known to contribute to these diseases. As used herein, dopaminergic CNS disorders include Parkinson's disease, Alzheimer's disease, Lewy body dementia (LBD), vascular dementia, schizophrenia, ADHD, depression, autism, chronic musculoskeletal pain, fibromyalgia, cognitive dysfunction, sleep disorders, excessive daytime sleepiness, narcolepsy, shift work disorder, traumatic brain injury, chronic traumatic encephalopathy, obesity and appetite regulation, mood disorders, lethargy, apathy, and addiction disorders. Identification of patients with these dopaminergic CNS disorders can be achieved by established methods known to those skilled in the art.
[0046] The present invention provides methods for the use of compounds of formula I, Ia, or Ib in simultaneous, separate, or sequential combination with dopamine precursors in the treatment of a dopaminergic disorder in a patient.The present invention provides methods for the use of compounds of formula I, Ia, or Ib in simultaneous, separate, or sequential combination with dopamine precursors in the treatment of Parkinson's disease in a patient.
[0047] The present invention provides methods for the use of compounds of Formula I, Ia, or Ib in simultaneous, separate, or sequential combination with a dopamine precursor in the treatment of Alzheimer's disease in a patient.
[0048] The present invention provides methods for the use of compounds of formula I, Ia, or Ib in simultaneous, separate, or sequential combination with a dopamine agonist in the treatment of a dopaminergic disorder in a patient.The present invention provides methods for the use of compounds of formula I, Ia, or Ib in simultaneous, separate, or sequential combination with a dopamine agonist in the treatment of Parkinson's disease in a patient.
[0049] The present invention provides methods for the use of compounds of Formula I, Ia, or Ib in simultaneous, separate or sequential combination with a dopamine agonist in the treatment of Alzheimer's disease in a patient.
[0050] In an embodiment of the present invention, the patient is a human who has been diagnosed with a medical risk, condition, or disorder, such as a dopaminergic CNS disorder, that requires treatment with the dosing regimen described herein. If the disorder that can be treated by the method of the present invention is known by an established and accepted classification, such as AD, PD, LBD, etc., those classifications can be found in various well-known medical books. For example, currently, the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) provides diagnostic tools for identifying many of the disorders described herein. Also, the International Classification of Diseases, 10th Edition (ICD-10) provides classifications for many of the disorders described herein. Those skilled in the art will recognize that there are alternative nomenclatures, nosologies, and classification systems for the disorders described herein, including those described in DSM-5 and ICD-10, and that terms and classification systems evolve with the advancement of medical science. Cognitive impairment in subjects with Parkinson's disease is generally referred to as neurocognitive disorder. The diagnostic criteria of the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) describe evidence of significant cognitive decline from a previous level of performance (personal or informant concerns documented by neuropsychological testing) and cognitive impairment that may or may not interfere with independence in daily living. This is qualified as a major or mild neurocognitive disorder. As used herein, "weight loss" refers to reduction in body weight and / or chronic weight management, where treatment promotes maintenance of weight within a desired range.
[0051] As used herein, the terms "treatment," "treating," or "mitigating" are intended to refer to any process, in which there may be a slowing, interrupting, preventing, controlling, or halting of an existing disorder and / or a reduction in its symptoms, but does not necessarily indicate a complete elimination of all symptoms.
[0052] As used herein, the term "effective amount" of a compound of formula I, Ia, or Ib refers to an amount, i.e., a dosage, that is effective in enhancing dopamine-mediated responses in a patient. A preferred "effective amount" can be determined as an amount that can promote the wakefulness or alertness of a patient, compared to an untreated patient. In determining the effective amount or dosage of a compound of formula I, Ia, or Ib, several factors are taken into consideration, including, but not limited to, the compound and its specific formulation to be administered; the size, age, and general health of the patient; the extent or severity of the involvement of the disorder; the response of the individual patient; the method of administration; and other relevant circumstances.
[0053] The abbreviations used herein are defined as follows: "Bn" refers to benzyl. "CAS#" refers to Chemical Abstracts Registry number. "Crotyl" refers to but-2-en-1-yl. "CNS" refers to the central nervous system. "1D-NOESY" refers to one-dimensional nuclear Overhauser effect NMR spectroscopy. "DCM" refers to dichloromethane or methylene chloride. "DIPEA" refers to N,N-diisopropylethylamine. "dmso-d6" refers to fully deuterated dimethyl sulfoxide. "ee" refers to enantiomeric excess. "ESMS" refers to electrospray mass spectrometry. "EtOAc" refers to ethyl acetate. "h" refers to hours. "HATU" refers to 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate or N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide. "HPLC" refers to high performance liquid chromatography. "LAH" refers to lithium aluminum hydride. "MeOH" refers to methanol or methyl alcohol. "Min" refers to minutes. "NMR" refers to nuclear magnetic resonance spectroscopy. "PG" refers to a protecting group. "Ph" refers to phenyl. "OAc" refers to acetate. "rac-" refers to racemic or racemic form. "RT" refers to room or ambient temperature. "SFC" refers to supercritical fluid chromatography. "TBDMS" refers to tert-butyldimethylsilyl; "TBDPS" refers to tert-butyldiphenylsilyl. "THF" refers to tetrahydrofuran. "t R " refers to retention time. "w / w" refers to weight with respect to weight as a unit of mass or weight by weight. "wt%" refers to percentage by weight. "Z" refers to the benzyloxycarbonyl protecting group, -C(O)OCH2Ph.
[0054] general chemistry The compounds of the present invention may be prepared by general methods known and recognized in the art or by the processes described herein. Suitable reaction conditions for the steps of these schemes are well known in the art, and appropriate substitution of solvents and co-reagents is within the skill of the art. Similarly, those skilled in the art will recognize that synthetic intermediates can be isolated and / or purified by various well-known techniques as necessary or desired, and frequently, various intermediates can be used directly in subsequent synthetic steps with little or no purification. Furthermore, those skilled in the art will recognize that in some circumstances, the order in which moieties are introduced is not important. Scheme 1 [ka]
[0055] Scheme 1 illustrates the preparation of compound 8. One skilled in the art can easily prepare an appropriately disubstituted phenylalanine 1 (e.g., X=Br, Cl, I, R), dissolved in a polar protic solvent to obtain the esterified salt 2. 4It will be appreciated that N-protected phenylalanine methyl esters (=H, F) can be esterified with a suitable strong acid. The salt can be washed with aqueous base to give the free base, and subsequent acylation can be achieved by dissolving in an aprotic solvent and adding a suitable acid chloride to give 3. Cyclization of 2-substituted N-acylated phenylalanine methyl esters 3 by treatment with paraformaldehyde in a suitable strong acid and stirring to give tetrahydroisoquinoline 4 is well known in the art. Demethylation and decarboxylation can be achieved by treatment with aqueous acid and stirring under reflux to give 5 as the corresponding amine salt. Those skilled in the art will appreciate that N-protected tetrahydroisoquinolines 6 can be formed by dissolving amine salts 5 in a suitable polar aprotic solvent and adding base and a suitable anhydride or alkyl chloroformate to give tert-butyl carbamates 6. Subsequent reduction to methanol derivatives 7 can be effected using a range of reducing agents such as metal hydrides, borohydrides, or diborane in polar aprotic solvents. The O-protected tetrahydroisoquinoline 8 can be achieved by first treating the N-protected tetrahydroisoquinoline 7 with a suitable strong acid and concentrating under vacuum. The amine salt can then be dissolved in a suitable aprotic solvent and treated with a base and a suitable protecting group (PG) (e.g., PG = OSi, OBn, OMOM, etc.) to provide 8. Protection of primary alcohols with acid-stable silyl groups, such as TBDMS or TBDPS, is well known in the art. Scheme 2 [ka]
[0056] Scheme 2 shows the synthesis of the required substituted intermediate 3 (e.g., X=Br, Cl, I, R 4 PG=Z)。 To prepare ene-carbamemate 15 (e.g., PG=Z), one skilled in the art can easily prepare an appropriately disubstituted benzaldehyde 13 (R 4Horner-Wadsworth-Emmons condensation between 14 (X = Br, Cl, I, R) and N-protected amino-2-dimethoxyphosphoryl acetate 14 can be used. Subsequent chiral reduction with an appropriate chiral auxiliary, for example under H2 with Rh(I) transition metal catalyst, as well described in the art, gives N-protected 16. Exchange of the N-protecting group can be achieved under a variety of conditions recognized by those skilled in the art to give 3. Subsequent conversion to compound 3 gives compound 8 (X = Br, Cl, I, R 4 ═F), can be carried out as in Scheme 1. Scheme 3 [ka]
[0057] Scheme 3 illustrates the synthesis of compounds of type I'. Imine formation from tetrahydroisoquinoline 8 can be achieved under a variety of oxidation conditions recognizable to one skilled in the art, specifically, halogenation of the secondary amine and subsequent elimination with a suitable strong base to provide dihydroisoquinoline 9. Stereoselective Grignard reaction can be used by treating imine 9 with a suitable alkyl magnesium halide to give trans tetrahydroisoquinoline 10. The relative configuration of tetrahydroisoquinoline 10 can be determined using appropriate NMR spectroscopic experiments, specifically, 1D-NOESY. Subsequent N-acylation can be achieved using amide coupling techniques well known in the art, for example, benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate in the presence of a mild non-nucleophilic base to prepare compound 11. Carbon-carbon bond formation using appropriately substituted compounds 11 (e.g., X=Br, Cl, I, etc.) can be effected with appropriate boronic esters or trifluoroborane salts under transition metal catalysis, such as using Pd, Pt, Ni, or Cu, as is well known in the art. Alternatively, coupling under Heck-type or Sonogashira-type conditions with appropriately substituted alkenes or alkynes, respectively, can be achieved, as is well known in the art. For example, palladium-mediated cross-coupling 11 with appropriately substituted cyclopropyl trifluoroborane can be achieved to give substituted cyclopropyl compounds of type 12. In addition, palladium-mediated cross-coupling 11 with appropriately substituted alkenes can be achieved to give alkyl-substituted compounds of type 12. Those skilled in the art will recognize that deprotection of protected alcohols 12, such as PG=OSi, OBn, OMOM, etc., can be carried out under a variety of conditions. For example, the silyl protecting group can be removed using tetrabutylammonium fluoride to give chiral compounds of type I'.
[0058] In the following exemplary preparations and examples, the solvent is generally removed (evaporated) under reduced pressure. In some procedures, the yields shown are representative crude yields of products that are isolated by evaporation or filtration and used directly without further purification. The relative stereochemistry around the described tetrahydroisoquinoline framework has been identified by appropriate NMR spectroscopy, especially 1D-NOESY. In the example of the configuration around the substituted cyclopropyl group in the side chain substitution, the relative configuration is described without determination of the absolute stereochemistry. In the example of the other chiral center in the side chain substitution, the absolute configuration has not been determined. In both of these examples, the diastereomeric pairs are designated as "isomer 1" or "isomer 2" when separated by chiral chromatographic techniques.
[0059] Preparation 1 Methyl 2-bromo-D-phenylalaninate hydrochloride [ka] 2-Bromo-D-phenylalanine (22.4 g, 91.8 mmol) is dissolved in MeOH (459 mL). Acetyl chloride (65.3 mL, 917.7 mmol) is added at room temperature and the resulting reaction mixture is stirred for 36 h. The reaction mixture is concentrated under reduced pressure to give the title compound (27.2 g, >99% yield). ESMS (m / z) 258 / 260 [M-Cl, 79 Br / 81 Br].
[0060] Preparation 2 Methyl 2-bromo-N-(methoxycarbonyl)-D-phenylalaninate [ka] Methyl 2-bromo-D-phenylalaninate hydrochloride (27.2 g, 92.3 mmol) is dissolved in a biphasic mixture of DCM (923 mL) and water (185 mL). NaHCO3 (31 g, 369.4 mmol) and methyl chloroformate (7.9 mL, 101.6 mmol) are added at room temperature and the resulting mixture is stirred for 2.5 h. The mixture is diluted with water and extracted with DCM. The organic extract is dried over Na2SO4, filtered and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel, eluting with a gradient of 10-75% EtOAc in hexanes to give, after solvent evaporation of the desired chromatographic fractions, the title compound (29.1 g, >99% yield). ESMS (m / z): 316 / 318 [M+H, 79 Br / 81 Br].
[0061] Preparation 3 (3R)-5-Bromo-3,4-dihydro-1H-isoquinoline-2,3-dicarboxylate dimethyl [ka] A mixture of methyl 2-bromo-N-(methoxycarbonyl)-D-phenylalaninate (29.1 g, 92.1 mmol) and paraformaldehyde (9.13 g, 101.3 mmol) is stirred in glacial acetic acid (115 mL, 2 mol) containing concentrated H2SO4 (38.4 mL, 719.9 mmol) at room temperature for 7 h. The reaction mixture is partitioned between water and EtOAc, the layers are separated, and the aqueous layer is extracted with EtOAc. The combined organic extracts are dried over Na2SO4, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel, eluting with a gradient of 5-40% EtOAc in hexanes to give, after solvent evaporation of the desired chromatographic fractions, the title compound (27.6 g, 91% yield). ESMS (m / z): 328 / 330 [M+H, 79 Br / 81 Br].
[0062] Preparation 4 (3R)-5-Bromo-1,2,3,4-tetrahydroisoquinoline-3-carboxylate methyl ester hydrochloride [ka] (3R)-5-bromo-3,4-dihydro-1H-isoquinoline-2,3-dicarboxylate dimethyl (27.6 g, 84 mmol) is dissolved in 5N HCl (330.6 mL, 1.7 mol) and the resulting mixture is heated to reflux for 3 days. The mixture is concentrated under reduced pressure to give a white solid. The solid is collected by filtration, washed with diethyl ether, and dried under vacuum at 40° C. overnight to give (3R)-5-bromo-1,2,3,4-tetrahydroisoquinoline-3-carboxylate hydrochloride (1:1) (20.8 g, 71.1 mmol). Acetyl chloride (50.6 mL, 711.0 mmol) is added to a 0° C. mixture of (3R)-5-bromo-1,2,3,4-tetrahydroisoquinoline-3-carboxylate hydrochloride (1:1) (20.8 g, 71.1 mmol) in MeOH (474 mL). The mixture is allowed to warm to room temperature and stirred for 36 hours. The mixture is concentrated under reduced pressure and dried to give the title compound (21.9 g, 85% yield). ESMS (m / z): 270 / 272 [M-Cl, 79 Br / 81 Br].
[0063] Preparation 5 2-tert-Butyl-3-methyl-(3R)-5-bromo-3,4-dihydro-1H-isoquinoline-2,3-dicarboxylate [ka] (3R)-Methyl 5-bromo-1,2,3,4-tetrahydroisoquinoline-3-carboxylate hydrochloride (21.0 g, 68.5 mmol) is dissolved in 1,4-dioxane (685 mL). Saturated aqueous NaHCO3 (685 mL, 17.5 mol) and di-tert-butyl dicarbonate (29.9 g, 137.0 mmol) are added at room temperature and the biphasic mixture is stirred at room temperature for 90 min. The mixture is extracted with EtOAc, the organic extract is dried over Na2SO4, filtered and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel, eluting with a gradient of 5-50% EtOAc in hexanes to yield, after solvent evaporation of the desired chromatographic fractions, the title compound (19.5 g, 77% yield). MS (m / z): 270 / 272 [M- t Boc+H, 79 Br / 81 Br].
[0064] Preparation 6 (3R)-5-Bromo-3-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate tert-butyl ester [ka] A 2M solution of lithium borohydride (99.4 mL, 198.8 mmol) and MeOH (10.1 mL, 248.5 mmol) in THF is added to a solution of 2-tert-butyl-3-methyl-(3R)-5-bromo-3,4-dihydro-1H-isoquinoline-2,3-dicarboxylate (18.4 g, 49.7 mmol) in THF (497 mL) and the resulting mixture is stirred at room temperature for 40 min. The reaction is quenched with water and extracted with EtOAc. The organic extract is separated, dried over Na2SO4, filtered and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel eluting with a gradient of 5-80% EtOAc in hexanes. The solvent is evaporated from the desired chromatographic fractions and the resulting residue is dried under high vacuum overnight to afford the title compound as a white solid (19.1 g, >99% yield). ESMS(m / z):286 / 288[M- t Bu+H,79 Br / 81 Br].
[0065] Preparation 7 [(3R)-5-Bromo-1,2,3,4-tetrahydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane [ka] Trifluoroacetic acid (75.5 mL, 998.3 mmol) is added to a solution of (3R)-5-bromo-3-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate tert-butyl (15.5 g, 45.3 mmol) in DCM (226 mL) at room temperature. The reaction mixture is stirred at room temperature for 30 min and concentrated under reduced pressure. The resulting residue is dried under vacuum to give [(3R)-5-bromo-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol 2,2,2-trifluoroacetic acid as a wet solid. [(3R)-5-bromo-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol 2,2,2-trifluoroacetic acid is dissolved in DCM (753 mL). 1H-imidazole (51.3 g, 753 mmol), N,N-dimethyl-4-pyridinamine (460 mg, 3.77 mmol), and t-butyldimethylchlorosilane (13.6 g, 90.4 mmol) are added and the resulting mixture is stirred overnight at room temperature. Saturated NH4Cl solution is added and the mixture is extracted with DCM. The DCM layer is separated, dried over Na2SO4, filtered, and the filtrate is concentrated under reduced pressure. (3R)-tert-butyl 5-bromo-3-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (6.6 g, 19.4 mmol) is combined with the crude product from essentially the same reaction run. The combined crude product is purified by flash chromatography on silica gel, eluting with a 5-40% gradient of EtOAc in hexanes to yield, after solvent evaporation of the desired chromatographic fractions, the title compound (14.3 g, 89% yield). ESMS(m / z):356 / 358[M+H, 79 Br / 81 Br].
[0066] Preparation 8 [(3R)-5-Bromo-3,4-dihydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane [ka] [(3R)-5-Bromo-1,2,3,4-tetrahydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane (4.2 g, 11.8 mmol) is dissolved in diethyl ether (118 mL) and N-chlorosuccinimide (2.36 g, 17.7 mmol) is added. The resulting mixture is stirred at room temperature for 30 min and concentrated under reduced pressure. The resulting residue is dissolved in a 5% solution of KOH in MeOH (42.0 mL, 30.3 mmol) and stirred at room temperature for 30 min. The mixture is poured into water and extracted with DCM. The DCM extract is dried over Na2SO4, filtered and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica eluting with a gradient of 5-100% EtOAc in hexane to give the title compound (3.40 g, 82% yield). ESMS (m / z): 354 / 356 [M+H, 79 Br / 81 Br].
[0067] Alternatively, N-chlorosuccinimide (106.7 g, 790 mmol) is added to a solution of [(3R)-5-bromo-3,4-dihydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane (220 g, 520 mmol) in THF (3.85 L) at room temperature in a suitable vessel with stirring for 30 min. The mixture is concentrated under reduced pressure and the residue is dissolved in KOH 5% w / w in methanol (2.2 L, 1.7 mol) with stirring for 30 min at room temperature. The mixture is added to water (3 L) and extracted three times with DCM (3 x 1 L). The combined organic extracts are dried over anhydrous MgSO4, filtered and the filtrate is concentrated under reduced pressure to give the title compound (210 g, >99% yield). ESMS (m / z): 354 / 356 [M+H, 79 Br / 81 Br].
[0068] Preparation 9 [(1S,3R)-5-Bromo-1-methyl-1,2,3,4-tetrahydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane [ka] [(3R)-5-bromo-3,4-dihydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane (3.4 g, 9.6 mmol) is dissolved in diethyl ether (160 mL) and cooled to -78 °C in a dry ice-acetone bath. A 3M solution of methylmagnesium chloride in THF (26.9 mL, 80.6 mmol) is added dropwise. The mixture is slowly warmed to room temperature and stirred overnight. The reaction mixture is slowly quenched by the addition of saturated NH4Cl solution. The resulting mixture is extracted with DCM, dried over NaSO4, filtered, and the filtrate is concentrated under reduced pressure. The crude product is combined with 1.7 mmol of [(3R)-5-bromo-3,4-dihydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane and material from essentially the same reaction run. The combined residues are purified by flash chromatography on silica eluting with a gradient of 5-65% EtOAc in hexanes to give, after evaporation of the solvent of the desired chromatographic fractions, the title compound (3.78 g, >99% yield). ESMS (m / z): 370 / 372 [M+H, 79 Br / 81 Br].
[0069] The relative configuration of the compound [(1S,3R)-5-bromo-1-methyl-1,2,3,4-tetrahydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane is determined by NMR spectroscopy using 1D-NOESY. Selective excitation of the methyl group at 1.30 ppm gives rise to a NOE for Ha at 3.11 ppm. This NOE enhancement is only consistent with a configuration in which the methyl and Ha are on the same side of the ring (trans isomer), because in the cis isomer the methyl protons are too far away from the Ha to show a NOE. Since the absolute chemistry at the 3 position is known to be R, the absolute chemistry at the 1 position is presumed to be S. [ka]
[0070] Preparation 10 1-[(1S,3R)-5-Bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2,6-dichlorophenyl)ethanone [ka] 2,6-Dichlorophenylacetic acid (3.7 g, 18 mmol) is combined with [(1S,3R)-5-bromo-1-methyl-1,2,3,4-tetrahydroisoquinolin-3-yl]methoxy-tert-butyl-dimethyl-silane (5 g, 13.5 mmol), HATU (7.7 g, 20 mmol), and DIPEA (7.1 mL, 41 mmol) in DCM (70 mL). The mixture is stirred at room temperature under a blanket of nitrogen for 2 h. The reaction solution is concentrated under reduced pressure and the resulting residue is purified by flash chromatography on silica gel eluting with a gradient of 0-25% EtOAc in hexanes to afford, after solvent evaporation of the desired chromatographic fractions, the title compound (6.2 g, 81% yield). ESMS (m / z): 558 (M+1).
[0071] Preparation 11 trans-Ethyl-2-[(1S,3R)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-[2-(2,6-dichlorophenyl)acetyl]-1-methyl-3,4-dihydro-1H-isoquinolin-5-yl]cyclopropanecarboxylate [ka] 1-[(1S,3R)-5-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2,6-dichlorophenyl)ethanone (500 mg, 0.9 mmol) is combined in a microwave vial with potassium [trans-2-ethoxycarbonylcyclopropyl]-trifluoro-borane (300 mg, 1.3 mmol, see PCT / FR2013 / 053057), KH2PO4 (370 mg, 2.7 mmol), and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (115 mg, 0.1 mmol) in 1,4-dioxane (8 mL, 93.2 mmol) and water (2 mL). The vial is capped, purged with nitrogen, and irradiated in a microwave for 2 hours at 120° C. The reaction solution is concentrated under reduced pressure and the resulting residue is purified by flash chromatography on silica gel, eluting with a gradient of 0-25% EtOAc in hexanes to afford, after solvent evaporation of the desired chromatographic fractions, the title compound as a mixture of trans isomers (245 mg, 46% yield). ESMS (m / z): 590 (M+1).
[0072] Preparation 12 1-[(1S,3R)-3-[[tert-Butyl(dimethyl)silyl]oxymethyl]-5-[trans-2-(2-hydroxy-2-methyl-propyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2,6-dichlorophenyl)ethanone [ka] Ethyl trans-2-[(1S,3R)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-[2-(2,6-dichlorophenyl)acetyl]-1-methyl-3,4-dihydro-1H-isoquinolin-5-yl]cyclopropanecarboxylate (240 mg, 0.4 mmol) is stirred in THF (4 ml) and cooled to 0° C. A 3M solution of methylmagnesium chloride in THF (1.75 mL, 5.25 mmol) is added dropwise via syringe at 0° C. over 5 min. The resulting mixture is stirred under nitrogen for 1 h, quenched with saturated aqueous NH4Cl, and extracted with EtOAc. The organic layer is separated, dried over Na2SO4, filtered, and the resulting filtrate is concentrated under reduced pressure to give the title compound as a mixture of trans isomers around the cyclopropyl substituent, suitable for use without further purification. ESMS (m / z): 576 (M+1).
[0073] Preparation 13 cis-2-[(1S,3R)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-[2-(2,6-dichlorophenyl)acetyl]-1-methyl-3,4-dihydro-1H-isoquinolin-5-yl]cyclopropanecarboxylate ethyl [ka] Using essentially the method described in Preparation 2, 1-[(1S,3R)-5-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2,6-dichlorophenyl)ethanone (500 mg, 0.9 mmol) is combined with potassium [cis-2-ethoxycarbonylcyclopropyl]-trifluoro-borane (WZ5-E16784-076-B, 300 mg, 1.3 mmol, see PCT / FR2013 / 053057) to give the title compound as a mixture of cis isomers (280 mg, 53% yield). ESMS (m / z): 590 (M+1).
[0074] Preparation 14 1-[(1S,3R)-3-[[tert-Butyl(dimethyl)silyl]oxymethyl]-5-[cis-2-(2-hydroxy-2-methyl-propyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2,6-dichlorophenyl)ethanone isomer 1 and 1-[(1S,3R)-3-[[tert-Butyl(dimethyl)silyl]oxymethyl]-5-[cis-2-(2-hydroxy-2-methyl-propyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2,6-dichlorophenyl)ethanone isomer 2 [ka] Using essentially the method described in Preparation 3, a mixture of ethyl cis-2-[(1S,3R)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-[2-(2,6-dichlorophenyl)acetyl]-1-methyl-3,4-dihydro-1H-isoquinolin-5-yl]cyclopropanecarboxylate (280 mg, 0.5 mmol) and a 3 M solution of methylmagnesium bromide in THF (2 mL, 6 mmol), followed by purification by flash chromatography on silica gel using a gradient of 0-25% EtOAc in hexanes, the title compound was isolated as the cis isomer, 1-[(1S,3R)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-[2-(2,6-dichlorophenyl)acetyl]-1-methyl-3,4-dihydro-1H-isoquinolin-5-yl]cyclopropanecarboxylate (280 mg, 0.5 mmol) and a 3 M solution of methylmagnesium bromide in THF (2 mL, 6 mmol). Silyl]oxymethyl]-5-[cis-2-(2-hydroxy-2-methyl-propyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2,6-dichlorophenyl)ethanone isomer 1 (110 mg, 38% yield) and 1-[(1S,3R)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-[cis-2-(2-hydroxy-2-methyl-propyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2,6-dichlorophenyl)ethanone isomer 2 (65 mg, 23% yield) are obtained after evaporation of the solvent of the desired chromatographic fractions. ESMS (m / z): 576 (M+1) for each.
[0075] Preparation 15 4-[(1S,3R)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-[2-(2-chloro-6-fluoro-phenyl)acetyl]-1-methyl-3,4-dihydro-1H-isoquinolin-5-yl]butan-2-one [ka] 1-[(1S,3R)-5-bromo-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2-chloro-6-fluoro-phenyl)ethanone (2 g, 3.7 mmol), tris(dibenzylideneacetone)dipalladium(0) (169 mg, 0.2 mmol), and di-tert-butyl-(1-phenylindol-2-yl)phosphane (187 mg, 0.55 mmol) are suspended in DMF (12.3 mL). N,N-dicyclohexylmethylamine (0.9 mL, 4 mmol) and but-3-en-2-ol (0.45 mL, 5.2 mmol) are added and the mixture is degassed by bubbling with nitrogen for 10 min. The reaction vessel is sealed and heated to 100 °C with stirring for 1.5 h. The reaction mixture is cooled to room temperature and diluted with EtOAc. The organic layer is separated, washed with saturated aqueous NaCl, dried over Na2SO4, filtered and concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel using a gradient of 5-30% EtOAc in hexanes to give, after solvent evaporation of the desired chromatographic fractions, the title compound as a white foam (1.5 g, 75% yield). ESMS (m / z): 532 (M+1).
[0076] Preparation 16 1-((1S,3R)-3-(((tert-butyldimethylsilyl)oxy)methyl)-5-((R)-4,4-difluoro-3-methyl-3-((trimethylsilyl)oxy)butyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-(2-chloro-6-fluorophenyl)ethan-1-one and 1-((1S,3R)-3-(((tert-butyldimethylsilyl)oxy)methyl)-5-((S)-4,4-difluoro-3-methyl-3-((trimethylsilyl)oxy)butyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-(2-chloro-6-fluorophenyl)ethan-1-one [ka] 4-[(1S,3R)-3-[[tert-Butyl(dimethyl)silyl]oxymethyl]-2-[2-(2-chloro-6-fluoro-phenyl)acetyl]-1-methyl-3,4-dihydro-1H-isoquinolin-5-yl]butan-2-one (580 mg, 1.1 mmol) and 18-crown-6 (29 mg, 0.1 mmol) are dissolved in 1,2-dimethoxyethane (5.5 mL). (Difluoromethyl)trimethylsilane (0.30 mL, 2 mmol) is added followed by CsF (17 mg, 0.1 mmol). The mixture is heated to 60° C. and stirred overnight. Additional (difluoromethyl)trimethylsilane (0.30 mL, 2 mmol), 18-crown-6 (29 mg, 0.1 mmol), and CsF (17 mg, 0.1 mmol) are added and the reaction mixture is stirred at 60° C. for 4 h. The mixture is cooled to room temperature, diluted with EtOAc, and the separated organic extract is washed with saturated aqueous NaCl. The organic layer is dried over Na2SO4, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica using a gradient of 0-10% EtOAc in hexanes to afford, after solvent evaporation of the desired chromatographic fractions, a mixture of the title compounds as a white foam (493 mg, 68% yield). ESMS (m / z): 656 (M+1).
[0077] Preparation 17 (Z)-2-(((benzyloxy)carbonyl)amino)-3-(2-bromo-3-fluorophenyl)acrylate methyl ester [ka] 2-(Benzyloxycarbonylamino)-2-dimethoxyphosphoryl-methyl acetate (25.5 g, 76.9 mmol) is dissolved in DCM (250 mL) and the solution is cooled to 0 °C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (12 mL, 79.9 mmol) is added and the mixture is stirred at 0 °C for 30 min. A solution of 2-bromo-3-fluoro-benzaldehyde (13.0 g, 64 mmol) in DCM (250 mL) is added slowly over 20 min at 0 °C. The mixture is stirred at 0 °C for 2 h. The mixture is transferred to a separatory funnel and washed successively with saturated aqueous NH4Cl solution (200 mL) and saturated aqueous NaCl (200 mL). The organic layer is dried over Na2SO4, filtered and the filtrate is concentrated under reduced pressure to give a white solid. The solid is recrystallized from hot EtOAc and collected by filtration to afford the title compound as a white solid (25 g, 80% yield). ESMS (m / z): 407 (M+1).
[0078] Preparation 18 (R)-2-(((benzyloxy)carbonyl)amino)-3-(2-bromo-3-fluorophenyl)propanoic acid methyl ester BMD-E17046-003 [ka] In a glovebox, (Z)-2-(((benzyloxy)carbonyl)amino)-3-(2-bromo-3-fluorophenyl)methyl acrylate (26 g, 63.8 mmol) is added to an autoclave vessel containing MeOH (300 mL). [((R)-tert-butylmethylphosphino)(di-tert-butylphosphino)amine](1,5-cyclooctadiene)rhodium(I) tetrafluoroborate (430 mg, 0.8 mmol) is added and the autoclave vessel is sealed and removed from the glovebox. The mixture is flushed with H2 gas for 15 seconds and pressurized to 100 psi of H2. The resulting mixture is stirred at room temperature for 15 hours. The autoclave vessel is evacuated and the mixture is concentrated under reduced pressure to give the title compound as a white solid suitable for use without further purification (26.3 g, 98% yield). ESMS (m / z): 410 (M+1).
[0079] To obtain an analytically pure sample, a portion of the crude product (66 mg) is purified by flash chromatography on silica gel eluting with 15% EtOAc in hexanes to give the product as a white solid after evaporation of the solvent of the desired chromatographic fractions. Chiral HPLC analysis (CHIRALCEL® OJ-H column, 0.2% isopropanol / MeOH, 1 mL / min): Major enantiomer t R : 2.981 min, minor enantiomer R : 3.557 min. Measurement value >99%ee.
[0080] Preparation 19 (R)-3-(2-bromo-3-fluorophenyl)-2-((methoxycarbonyl)amino)propanoic acid methyl ester [ka] Methyl (R)-2-(((benzyloxy)carbonyl)amino)-3-(2-bromo-3-fluorophenyl)propanoate (21.25 g, 51.8 mmol) is dissolved in DCM (110 mL) and a 33% solution of HBr in acetic acid (28.1 mL, 155 mmol) is added. The resulting mixture is stirred at room temperature for 1 h. Water (100 mL) and DCM (100 mL) are added and the resulting mixture is stirred vigorously for 15 min. The organic layer is separated and discarded. DCM (200 mL) and Na2CO3 (35.1 g, 331.5 mmol) are added to the aqueous layer. Methyl chloroformate (5.2 mL) is added to the mixture and the resulting mixture is stirred at room temperature overnight. The mixture is extracted with DCM. The combined organic extracts are washed with saturated aqueous NaCl, dried over Na2SO4, filtered, and the filtrate is concentrated under reduced pressure to give the title compound as a white solid (13.6 g, 78% yield). ESMS (m / z): 333 (M+1).
[0081] Preparation 20 (R)-5-Bromo-6-fluoro-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride [ka] (R)-Methyl 3-(2-bromo-3-fluorophenyl)-2-((methoxycarbonyl)amino)propanoate (17 g, 50.9 mmol) and paraformaldehyde (6.9 g, 76.4 mmol) are suspended in acetic acid (128 mL). The solution is cooled to 0° C. and concentrated H2SO4 (43 mL) is added. The resulting mixture is heated to 35° C. and stirred overnight. The reaction mixture is cooled to room temperature and poured into water (200 mL). The resulting suspension is extracted with EtOAc, the combined organic extracts are washed with saturated aqueous NaCl, dried over Na2SO4, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is dissolved in concentrated HCl (231 mL) and the resulting mixture is heated to 120° C. in a round-bottom flask equipped with a reflux condenser overnight. The reaction mixture is cooled to room temperature and concentrated under reduced pressure at 50° C. The resulting residue is dried under vacuum at 40° C. for 18 hours to give the title compound as a colorless solid (15 g, 94% yield). ESMS (m / z): 273 (M+1).
[0082] Preparation 21 (R)-(5-Bromo-6-fluoro-1,2,3,4-tetrahydroisoquinolin-3-yl)methanol [ka] (R)-5-Bromo-6-fluoro-1,2,3,4-tetrahydroisoquinoline-3-carboxylate hydrochloride (9.95 g, 32.0 mmol) is suspended in THF (80 mL) and the mixture is cooled to 0° C. A 1 M solution of borane-tetrahydrofuran complex (96 mL, 96 mmol) is slowly added. The mixture is heated to 60° C. and stirred overnight. The reaction mixture is cooled to 0° C., MeOH (20 mL) and saturated aqueous NH4Cl solution (40 mL) are added, and the mixture is stirred at room temperature for 10 min. Aqueous 5N HCl (60 mL) is added, and the resulting mixture is heated to 45° C. for 4 h. The mixture is cooled to 0° C. and 21 wt % concentrated aqueous NH4OH is added. The mixture is allowed to warm to room temperature. The resulting mixture is extracted with 3:1 CHCl3:isopropanol. The combined organic extracts are washed with saturated aqueous NaCl, dried over Na2SO4, filtered, and the filtrate is concentrated under reduced pressure to give the title compound as a beige solid (9.5 g, 86% yield). ESMS (m / z): 259 (M+1).
[0083] Preparation 22 (R)-5-Bromo-3-(((tert-butyldiphenylsilyl)oxy)methyl)-6-fluoro-1,2,3,4-tetrahydroisoquinoline [ka] (R)-(5-Bromo-6-fluoro-1,2,3,4-tetrahydroisoquinolin-3-yl)methanol (12.6 g, 48.3 mmol) is dissolved in a mixture of DCM (185 mL) and DMF (146 mL). Imidazole (16.4 g, 241.5 mmol) and 4,4-dimethylaminopyridine (118 mg, 1 mmol) are added, followed by tert-butylchlorodiphenylsilane (13.8 mL, 53.1 mmol). The resulting mixture is stirred at room temperature for 1 h. MeOH (100 mL) is added and the mixture is stirred for an additional 1 h. Saturated aqueous NH4Cl solution (200 mL) is added and the mixture is extracted with DCM. The combined organic extracts are washed with saturated aqueous NaCl, dried over Na2SO4, filtered and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel, eluting with a gradient of 2-50% EtOAc in hexanes to give, after evaporation of the solvent of the desired chromatographic fractions, the title compound as an oil (10.5 g, 45% yield). ESMS (m / z): 498 M+1).
[0084] Preparation 23 (R)-5-Bromo-3-(((tert-butyldiphenylsilyl)oxy)methyl)-6-fluoro-3,4-dihydroisoquinoline [ka] (R)-5-bromo-3-(((tert-butyldiphenylsilyl)oxy)methyl)-6-fluoro-1,2,3,4-tetra-hydisoquinoline (10.9 g, 21.9 mmol) is dissolved in THF (200 mL) and N-chlorosuccinimide (4.4 g, 32.9 mmol) is added. The resulting mixture is stirred at room temperature for 40 min and concentrated under reduced pressure. The resulting residue is dissolved in 0.75 M KOH in MeOH (100 mL) and stirred at room temperature for 30 min. The reaction mixture is diluted with water (50 mL) and extracted with DCM. The combined organic extracts are washed with saturated aqueous NaCl, dried over Na2SO4, filtered and the filtrate is concentrated. The resulting residue is purified by flash chromatography on silica gel eluting with a gradient of 5-50% EtOAc in hexane to give, after solvent evaporation of the desired chromatographic fractions, the title compound as a colorless oil (9.63 g, 88% yield). ESMS(m / z):496(M+1).
[0085] Preparation 24 (1S,3R)-5-Bromo-3-(((tert-butyldiphenylsilyl)oxy)methyl)-6-fluoro-1-methyl-1,2,3,4-tetrahydroisoquinoline [ka] (R)-5-Bromo-3-(((tert-butyldiphenylsilyl)oxy)methyl)-6-fluoro-3,4-dihydroisoquinoline (7.5 g, 15 mmol) is dissolved in tert-butyl methyl ether (190 mL) under nitrogen and the solution is cooled to -15 °C. A 3M solution of methylmagnesium chloride in THF (20 mL, 60 mmol) is added dropwise with stirring and the reaction mixture is allowed to warm to room temperature and stirred for an additional 2 h. The mixture is cooled to 0 °C and MeOH (4 mL) and saturated aqueous NH4Cl (4 mL) are added successively. The resulting mixture is extracted with DCM. The combined organic extracts are washed with saturated aqueous NaCl, dried over Na2SO4, filtered and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel eluting with a gradient of 2-5% tert-butyl methyl ether in DCM to yield, after solvent evaporation of the desired chromatographic fractions, the title compound as a yellow oil (1.7 g, 23% yield). ESMS(m / z):512(M+1).
[0086] Preparation 25 1-[(1S,3R)-5-Bromo-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-6-fluoro-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2-chloro-6-fluoro-phenyl)ethanone [ka] (1S,3R)-5-Bromo-3-(((tert-butyldiphenylsilyl)oxy)methyl)-6-fluoro-1-methyl-1,2,3,4-tetrahydroisoquinoline (5.2 g, 10.1 mmol) is dissolved in DMF (101 mL). 2-(2-Chloro-6-fluoro-phenyl)acetic acid (2.5 g, 13.2 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (5 g, 13.2 mmol), and DIPEA (8.8 mL, 50.6 mmol) are added successively and the resulting mixture is stirred at room temperature overnight. Water (200 mL) is added and the mixture is extracted with EtOAc. The combined organic extracts are washed with saturated aqueous NaCl, dried over Na2SO4, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel, eluting with a gradient of 0-25% EtOAc in hexanes to give, after evaporation of the solvent of the desired chromatographic fractions, the title compound as a white foam (6.3 g, 91% yield). ESMS (m / z): 682 (M+1).
[0087] Preparation 26 1-[(1S,3R)-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-6-fluoro-5-(3-hydroxy-3-methyl-but-1-ynyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2-chloro-6-fluoro-phenyl)ethanone [ka] Add 1-[(1S,3R)-5-bromo-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-6-fluoro-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2-chloro-6-fluoro-phenyl)ethanone (5.8 g, 8.5 mmol), tri-tert-butylphosphine(chloro)(crotyl)palladium(II) (675 mg, 1.7 mmol), and cuprous 2-thiophenecarboxylate (258 mg, 1.35 mmol) to a 500 mL round-bottom flask. Evacuate the flask and backfill with nitrogen. Add DMF (60 mL), DIPEA (6 mL, 42.5 mmol), and 2-methylbut-3-yn-2-ol (4.1 mL, 42.2 mmol). Heat the reaction mixture to 40° C. and stir overnight. The mixture is cooled to room temperature, diluted with EtOAc, and the phases are separated. The organic layer is washed successively with water and saturated aqueous NaCl, dried over Na2SO4, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel, eluting with a gradient of 20-40% EtOAc in hexanes, to give, after solvent evaporation of the desired chromatographic fractions, the title compound as a white foam (5.4 g, 93% yield). ESMS (m / z): 686 (M+1).
[0088] Preparation 27 1-[(1S,3R)-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-6-fluoro-5-(3-hydroxy-3-methyl-butyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2-chloro-6-fluoro-phenyl)ethanone [ka] Purge the Parr shaker with nitrogen and add 5 wt% platinum sulfide on carbon (2.5 g). Purge the vessel again with nitrogen. Add EtOAc (50 mL). Add a solution of 1-[(1S,3R)-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-6-fluoro-5-(3-hydroxy-3-methyl-but-1-ynyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2-chloro-6-fluoro-phenyl)ethanone (5.4 g, 7.9 mmol) dissolved in EtOAc (50 mL). Purge the reaction vessel with H2 gas and pressurize to 60 psi of H2. Shake the reaction mixture at room temperature for 3 h. Add an additional 5 wt% platinum sulfide on carbon (1.21 g) suspended in EtOAc (30 mL) and repressurize the vessel to 60 psi of H2. The reaction vessel is shaken for an additional 8 hours. The vessel is depressurized and purged with nitrogen. The resulting suspension is filtered and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel, eluting with a gradient of 0-100% EtOAc in hexanes (gradient 0-100%) to give, after solvent evaporation of the desired chromatographic fractions, the title compound as a white foam (5.33 g, 7.72 mmol). MS (m / z): 690.4 (M+1).
[0089] Preparation 28 trans-2-((1S,3R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(2-(2-chloro-6-fluorophenyl)acetyl)-6-fluoro-1-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)cyclopropane-1-carboxylate ethyl [ka] 1-[(1S,3R)-5-bromo-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-6-fluoro-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2-chloro-6-fluoro-phenyl)ethanone (665 mg, 1 mmol), potassium rac-[(trans-2-ethoxycarbonylcyclopropyl)-trifluoroborate (CAS#161 2792-88-7, see PCT / FR2013 / 053057, December 12, 2013) (257 mg, 1.2 mmol), di(1-adamantanyl)-n-butyl-phosphonium iodide (50 mg, 0.1 mmol), [(di(1-adamantyl)-butylphosphine)-2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (75 mg, 0 Cs2CO3 (631 mg, 1.9 mmol) are suspended in a mixture of toluene (10 mL) and water (1 mL). The mixture is degassed with nitrogen for 5 min, the vial is sealed and heated to 100 °C with stirring overnight. The reaction mixture is cooled to room temperature and diluted with EtOAc. The resulting mixture is washed successively with water, saturated aqueous NaHCO3, water and saturated aqueous NaCl and the layers are separated. The organic phase is dried over MgSO4, filtered and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel eluting with a gradient of 0-100% ethyl tert-butyl ether in hexanes to give, after solvent evaporation of the desired chromatographic fractions, a mixture of the title compounds as a yellow solid (448 mg, 61% yield). ESMS (m / z): 716 (M+1).
[0090] Preparation 29 1-[(1R,3R)-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-6-fluoro-5-[(trans-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2-chloro-6-fluoro-phenyl)ethanone [ka] A mixture of trans-2-((1S,3R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(2-(2-chloro-6-fluorophenyl)acetyl)-6-fluoro-1-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)cyclopropane-1-carboxylate isomer 1 and trans-2-((1S,3R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(2-(2-chloro-6-fluorophenyl)acetyl)-6-fluoro-1-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)cyclopropane-1-carboxylate isomer 2 (440 mg, 0.6 mmol) is dissolved in THF (4 mL) and cooled to 0 °C. A 1M solution of methylmagnesium bromide in THF (1.4 mL, 1.4 mmol) is added slowly over 10 min, and the resulting reaction mixture is allowed to warm to room temperature and stirred overnight. The reaction mixture is cooled to 0° C., and an additional 1M solution of methylmagnesium bromide in THF (1.4 mL, 1.4 mmol) is added. The reaction mixture is allowed to warm to room temperature and stirred for 8 h. The mixture is quenched with MeOH (130 μL) and stirred at room temperature overnight. The reaction mixture is diluted with EtOAc, and the resulting solution is washed successively with saturated aqueous NaHCO3, water, and saturated aqueous NaCl. The layers are separated, and the organic phase is dried over MgSO4 and filtered. The filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel, eluting with a gradient of 0-100% methyl tert-butyl ether in hexanes to give, after solvent evaporation of the desired chromatographic fractions, a mixture of the title compounds as a yellow solid (245 mg, 42% yield). ESMS(m / z):702(M+1).
[0091] Preparation 30 1-[(1S,3R)-5-Bromo-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-6-fluoro-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2,6-dichlorophenyl)ethanone [ka] (1S,3R)-5-Bromo-3-(((tert-butyldiphenylsilyl)oxy)methyl)-6-fluoro-1-methyl-1,2,3,4-tetrahydroisoquinoline (500 mg, 1 mmol), 2-(2,6-dichlorophenyl)acetic acid (260 mg, 1.3 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (482 mg, 1.3 mmol) are suspended in DMF (10 mL). DIPEA (0.85 mL, 4.9 mL) is added and the mixture is stirred at room temperature for 72 h. The reaction mixture is diluted with EtOAc and washed successively with water and saturated aqueous NaCl. The layers are separated, the organic layer is dried over Na2SO4, filtered and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel, eluting with a gradient of 5-15% EtOAc in hexanes to give, after evaporation of the solvent of the desired chromatographic fractions, the title compound as a white foam (680 mg, 0.97 mmol). ESMS (m / z): 698 (M+1).
[0092] Preparation 31 Ethyl trans 2-[(1S,3R)-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-2-[2-(2,6-dichlorophenyl)acetyl]-6-fluoro-1-methyl-3,4-dihydro-1H-isoquinolin-5-yl]cyclopropanecarboxylate [ka] 1-[(1S,3R)-5-bromo-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-6-fluoro-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2,6-dichlorophenyl)ethanone (604 mg, 0.9 mmol), potassium rac-[(trans-2-ethoxycarbonylcyclopropyl]-trifluoroborate (CAS#1612792- 88-7, PCT / FR2013 / 053057, December 12, 2013) (228 mg, 1 mmol), di(1-adamantanyl)-n-butyl-phosphonium iodide (44 mg, 0.1 mmol), [(di(1-adamantyl)-butylphosphine)-2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (66 mg, 0.1 mmol), and and Cs2CO3 (565 mg, 1.7 mmol) are suspended in a mixture of toluene (10 mL) and water (1 mL). The resulting mixture is sparged with nitrogen for 5 min, the reaction is sealed, and the mixture is heated to 100 °C with stirring overnight. The reaction mixture is cooled to room temperature, diluted with EtOAc, and washed successively with water, saturated aqueous NaHCO3, water, and saturated aqueous NaCl. The layers are separated, the organic phase is dried over MgSO4, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel, eluting with a gradient of 0-100% methyl tert-butyl ether in hexanes to give, after solvent evaporation of the desired chromatographic fractions, the title compound as a mixture of trans diastereomers as a yellow solid (417 mg, 64% yield). ESMS (m / z): 732 (M+1).
[0093] Preparation 32 1-[(1S,3R)-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-6-fluoro-5-[trans-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2,6-dichlorophenyl)ethanone [ka] A mixture of trans 2-[(1S,3R)-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-2-[2-(2,6-dichlorophenyl)acetyl]-6-fluoro-1-methyl-3,4-dihydro-1H-isoquinolin-5-yl]cyclopropanecarboxylate isomer 1 and trans 2-[(1S,3R)-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-2-[2-(2,6-dichlorophenyl)acetyl]-6-fluoro-1-methyl-3,4-dihydro-1H-isoquinolin-5-yl]cyclopropanecarboxylate isomer 2 (405 mg, 0.6 mmol) is dissolved in THF (3 mL) and the mixture is cooled to 0° C. A 1 M solution of methylmagnesium bromide in THF (2.8 mL, 2.8 mmol) is added slowly over 10 min and the reaction mixture is allowed to warm to room temperature and stirred overnight. The reaction mixture is cooled to 0° C. and quenched with MeOH (220 μL). The reaction mixture is diluted with EtOAc and washed successively with water and saturated aqueous NaCl. The layers are separated, the organic phase is dried over MgSO4, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel, eluting with a gradient of 0-100% methyl tert-butyl ether in hexanes to afford, after solvent evaporation of the desired chromatographic fractions, the title compound as a mixture of trans diastereomers as a yellow solid (336 mg, 55% yield). ESMS (m / z): 718 (M+1).
[0094] Examples 1 and 2 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-[trans-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 1 and 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-[trans-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 2 [ka] A 1 M solution of tetrabutylammonium formate in THF (0.8 mL) is added to a solution of 1-[(1S,3R)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-[(trans-2-(2-hydroxy-2-methyl-propyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2,6-dichlorophenyl)ethanone (170 mg, 0.3 mmol) in THF (2.5 mL) and the resulting mixture is stirred for 30 min. The reaction mixture is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel eluting with a gradient of 0-65% EtOAc in hexanes and further purified by flash chromatography on silica gel eluting with a gradient of 0-50% EtOAc in DCM to give the title compound, 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5- [trans-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 2 (20 mg, 14% yield) is obtained after solvent evaporation of the desired chromatographic fractions. The combined fractions from the additional flash chromatography are further purified by reverse phase chromatography on 18C silica gel using a gradient of 5-95% water containing ammonium bicarbonate in acetonitrile to obtain the title compound, 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-[trans-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 1 (26 mg, 18% yield) after solvent evaporation of the desired chromatographic fractions. ESMS (m / z) of each: 462 (M+1). 1H nmr (400MHz, dmso-d6) isomer 1:δ 0.66-1.01(m, 4H), 1.08-1.27(m, 6H), 1.40-1.89(m, 1H), 2.00-2.08(m, 1H), 2.66-3.04(m, 2H), 3.20-3.32(m, 2H), 3.6 3-3.75(m, 1H), 4.09-4.31(m, 3H), 4.38-4.50(m, 1H), 4.98-5.25(m, 2H), 6.88-7.16(m, 3H), 7.33(t, 1H), 7.48(d, 2H). 1 H nmr (400MHz, dmso-d6) isomer 2:δ 0.66-1.01(m, 4H), 1.06-1.31(m, 5H), 1.40-1.89(m, 2H), 1.99-2.05(m, 1H), 2.67-3.00(m, 2H), 3.24-3.32(m, 2H), 3.6 6-3.77(m, 1H), 4.09-4.01(m, 3H), 4.40-4.49(m, 1H), 4.98-5.25(m, 2H), 6.92-7.15(m, 3H), 7.34(t, 1H), 7.48(d, 2H).
[0095] Examples 3 and 4 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-[cis-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 1 and 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-[cis-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 2 [ka] Using the methods essentially described in Examples 1 and 2, 1-[(1S,3R)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-[cis-2-(2-hydroxy-2-methyl-propyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2,6-dichlorophenyl)ethenone isomer 1 (100 mg, 173 mmol) is used to give the title compound 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-[cis-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 1 (61 mg, 76% yield). ESMS (m / z): 462 (M+1). 1 H nmr (400MHz, dmso-d6) isomer 1:δ 0.55(s, 1H), 0.65(s, 2H), 0.94-1.00(m, 2H), 1.07-1.22(m, 7H), 1.40-1.49(m, 2H), 1.98-2.07(m, 1H), 2.60-3.15(m, 2H), 3.20-3.29(m, 1) H), 3.53-3.65(m, 1H), 4.09-4.34(m, 2H), 4.37-4.48(m, 1H), 4.98-5.34(m, 2H), 7.00-7.22(m, 3H), 7.30-7.37(m, 1H), 7.45-7.51(m, 2H).
[0096] Using the methods essentially described in Examples 1 and 2, 1-[(1S,3R)-3-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-[cis-2-(2-hydroxy-2-methyl-propyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2,6-dichlorophenyl)ethenone isomer 2 (60 mg, 104 mmol) is used to give the title compound 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-[cis-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 2 (42 mg, 87% yield). Each ESMS (m / z): 462 (M+1). 1H nmr (400MHz, dmso-d6) isomer 1:δ 0.81(s, 3H), 0.83-0.94(m, 4H), 1.14-1.26(m, 5H), 1.28-1.37(m, 1H), 1.50(d, 1H), 2.09-2.18(m, 1H), 2.66-3.05(m, 2H), 3.27-3.3 2(m, 1H), 3.56-3.67(m, 1H), 4.08-4.32(m, 2H), 4.39-4.48(m, 1H), 4.96-5.26(m, 2H), 7.00-7.16(m, 3H), 7.33(t, 1H), 7.48(d, 2H).
[0097] Examples 5 and 6 2-(2,6-dichlorophenyl)-1-[(1S,3R)-5-[4,4-difluoro-3-hydroxy-3-methyl-butyl]-3-(hydroxymethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 1 and 2-(2,6-dichlorophenyl)-1-[(1S,3R)-5-[4,4-difluoro-3-hydroxy-3-methyl-butyl]-3-(hydroxymethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 2 [ka] 2-(2,6-dichlorophenyl)-1-[(1S,3R)-5-[(3R)-4,4-difluoro-3-hydroxy-3-methyl-butyl]-3-(hydroxymethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone and 2-(2,6-dichlorophenyl)-1-[(1S,3R)-5-[(3S)-4,4-difluoro-3-hydroxy-3-methyl-butyl]-3-(hydroxymethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone (493 mg, 0.75 mmol) are dissolved in THF (12 mL). A 1 M solution of tetrabutylammonium fluoride in THF (3 mL, 3 mmol) is added and the resulting mixture is stirred at room temperature for 1 h. The mixture is diluted with EtOAc and washed with saturated aqueous NaCl. The organic layer is separated, dried over Na2SO4, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel using a gradient of 0-75% EtOAc in hexanes to give, after evaporation of the desired chromatographic fractions, the title mixture as a white foam (342 mg, 97% yield). ESMS (m / z): 470 (M+1).
[0098] The two diastereomers were further purified and separated by chiral SFC (CHIRALCEL® OD-H column, 21×250 mm) eluting with methanol:CO (15:85) at a flow rate of 80 mL / min and a temperature of 40° C. to give Isomer 1 (156 mg, 46% yield) and Isomer 2 (141 mg, 41% yield) after solvent evaporation of the desired chromatographic fractions. Isomer 1: ESMS (m / z): 470 (M+H). Analysis SFC t R : 1.618 min (CHIRALCEL® OD-H column, 4x150 mm, 15% methanol / CO2, 5 mL / min, 225 nm). Isomer 2: ESMS (m / z): 470 (M+H). Analysis SFC t R : 2.213 min (CHIRALCEL® OD-H column, 4x150 mm, 15% methanol / CO2, 5 mL / min, 225 nm).
[0099] Example 7 2-(2-chloro-6-fluoro-phenyl)-1-[(1S,3R)-6-fluoro-3-(hydroxymethyl)-5-(3-hydroxy-3-methyl-butyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone [ka] 1-((1S,3R)-3-(((tert-butyldiphenylsilyl)oxy)methyl)-6-fluoro-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)-2-(2-chloro-6-fluorophenyl)ethan-1-one (5.3 g, 7.7 mmol) is dissolved in THF (129 mL) and a 1 M solution of tetrabutylammonium fluoride in THF (23 mL, 23 mmol) is added. The mixture is stirred at room temperature for 1 h. The mixture is diluted with EtOAc, washed with saturated aqueous NaCl, and the layers are separated. The organic extract is dried over Na2SO4, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel, eluting with a gradient of 50-100% EtOAc in hexanes to give, after solvent evaporation of the desired chromatographic fractions, the title compound as a white solid (2.75 g, 79% yield). ESMS(m / z):452(M+1).
[0100] Examples 8 and 9 2-(2-chloro-6-fluoro-phenyl)-1-[(1R,3R)-6-fluoro-3-(hydroxymethyl)-5-[trans-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 1 and 2-(2-chloro-6-fluoro-phenyl)-1-[(1R,3R)-6-fluoro-3-(hydroxymethyl)-5-[trans-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 2 [ka] A mixture of 1-[(1R,3R)-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-6-fluoro-5-[trans-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2-chloro-6-fluoro-phenyl)ethanone isomer 1 and 1-[(1R,3R)-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-6-fluoro-5-[trans-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2-chloro-6-fluoro-phenyl)ethanone isomer 2 (1.1 g, 1.5 mmol) is dissolved in THF (10 mL) and the mixture is cooled to 0 ° C. A 1M solution of tetrabutylammonium fluoride in THF (3 mL, 3 mmol) is added dropwise and the reaction mixture is stirred overnight while warming to room temperature. The reaction mixture is diluted with EtOAc and washed successively with water and saturated aqueous NaCl. The resulting layers are separated, the organic layer is dried over MgSO4, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel, eluting with a gradient of 0-100% methyl tert-butyl ether in hexanes to give, after solvent evaporation of the desired chromatographic fractions, a mixture of the title compounds as an amber oil (490 mg, 69% yield). ESMS (m / z): 464 (M+1).
[0101] The two diastereomers were further purified and separated by chiral SFC (PHENOMENEX® LUX® Cellulose-2 column, 21×250 mm, 20% isopropanol / CO2, 80 mL / min, 40° C.) to give 2-(2-chloro-6-fluoro-phenyl)-1-[(1R,3R)-6-fluoro-3-(hydroxymethyl)-5-[trans-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 1 (136 mg, 28% yield, analytical HPLC t R: 2.769 min) and 2-(2-chloro-6-fluoro-phenyl)-1-[(1R,3R)-6-fluoro-3-(hydroxymethyl)-5-[trans-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 2 (121 mg, 25% yield, analytical HPLC t R : 3.368 min) is obtained as a white solid after evaporation of the solvent of the desired chromatographic fractions.
[0102] Isomer 1: ESMS (m / z): 464 (M+H). 1 H NMR (400MHz, CDCl3):δ 0.94-1.17(m, 2H), 1.17-1.25(m, 3H), 1.25-1.44(m, 4H), 1.60(s, 3H), 1.80-1.90(m, 1H), 2.07-2.37(m, 1H), 2.91-3.23(m, 3H) , 3.47-3.57(m, 1H), 3.92(t, J=16.1Hz, 1H), 4.05(s, 2H), 4.42-4.66(m, 1H), 5.04(q, J=7.0Hz, 0.5H), 5.21(q, J=7.0Hz, 0.5H). 6.83-7.09(m, 3H), 7.19-7.26(m, 2H). Analysis SCF t R 2.769 min (PHENOMENEX® LUX® Cellulose-2 column, 4x150 mm, 20% isopropanol / CO2, 5 mL / min, 225 nm).
[0103] Isomer 2: ESMS (m / z): 464 (M+H). 1H NMR (400MHz, CDCl3):δ 0.71-0.81(m, 1H), 1.22(s, 3H), 1.24(s, 3H), 1.33-1.44(m, 4H), 1.48-1. 59(m, 1H), 1.59-1.69(m, 2H), 1.69-1.81(m, 1H), 2.87-3.08(m, 1H), 3.08- 3.31(m, 1H), 3.47-3.57(m, 1H), 3.70-3.95(m, 1H), 3.97-4.11(m, 2H), 4. 43-4.60(m, 1H), 5.01-5.26(m, 1H), 6.84-7.08(m, 3H), 7.20-7.26(m, 2H). Analysis SFC t R 3.368 min (PHENOMENEX® LUX® Cellulose-2 column, 4x150 mm, 20% isopropanol / CO2, 5 mL / min, 225 nm).
[0104] Examples 10 and 11 2-(2,6-dichlorophenyl)-1-[(1S,3R)-6-fluoro-3-(hydroxymethyl)-5-[trans-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 1 and 2-(2,6-dichlorophenyl)-1-[(1S,3R)-6-fluoro-3-(hydroxymethyl)-5-[trans-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 2 [ka] A mixture of 1-[(1S,3R)-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-6-fluoro-5-[trans-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2,6-dichlorophenyl)ethanone isomer 1 and 1-[(1S,3R)-3-[[tert-butyl(diphenyl)silyl]oxymethyl]-6-fluoro-5-[trans-2-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]-2-(2,6-dichlorophenyl)ethanone isomer 2 (333 mg, 0.5 mmol) is dissolved in THF (4.6 mL) and the mixture is cooled to 0 °C. A 1M solution of tetrabutylammonium fluoride in THF (0.50 mL, 0.50 mmol) is added dropwise and the resulting reaction mixture is allowed to warm to room temperature with stirring overnight. The reaction mixture is diluted with EtOAc and washed successively with water and saturated aqueous NaCl. The layers are separated, the organic phase is dried over MgSO4, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by flash chromatography on silica gel, eluting with a gradient of 0-100% methyl tert-butyl ether in hexanes to give, after solvent evaporation of the desired chromatographic fractions, a mixture of the title compounds as an amber oil (211 mg, 72% yield). ESMS (m / z): 480 (M+1).
[0105] The two diastereomers were further purified and separated by chiral SFC (PHENOMENEX® LUX® Cellulose-2 column, 21×250 mm, 20% IPA / CO2, 80 mL / min, 40° C.) to give the title compound 2-(2,6-dichlorophenyl)-1-[(1S,3R)-6-fluoro-3-(hydroxymethyl)-5-[trans-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 1 (41 mg, 21% yield, analytical HPLC t R: 3.095 min) and 2-(2,6-dichlorophenyl)-1-[(1S,3R)-6-fluoro-3-(hydroxymethyl)-5-[trans-(1-hydroxy-1-methyl-ethyl)cyclopropyl]-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, isomer 2 (47 mg, 24% yield, analytical HPLC t R : 3.793 min) is obtained as a white solid after evaporation of the solvent of the desired chromatographic fractions.
[0106] Isomer 1: ESMS (m / z): 480 (M+H). 1 H NMR (400MHz, CDCl3): δ 0.92-1.07(m, 2H), 1.20-1.27(m, 5H), 1.60-1.66(d, J=6.6Hz, 1H), 1.80-1.90(m, 1H). 2.93-3.23(m, 2H), 3.47-3.60(m, 1H), 3.81-4.00(m, 1H), 4.23(s, 2H), 4.44-4.70(m, 1H), 5.06(q, J= 6.7Hz, 0.5H), 5.23(q, J=6.7Hz, 0.5H), 6.84-7.04(m, 2H), 7.16-7.23(m, 1H), 7.36(d, J=8.1Hz, 2H). Analysis SFC t R 3.095 min (PHENOMENEX® LUX® Cellulose-2 column, 4.6x150 mm, 20% IPA / CO2, 5 mL / min, 225 nm).
[0107] Isomer 2: ESMS (m / z): 480 (M+H). 1H NMR (400 MHz, CDCl3): δ 0.70-0.83(m, 1H), 1.09-1.18(m, 1H), 1.23(d, J=6.1Hz, 1H), 1.32(s, 3H) , 1.35-1.46(m, 4H), 1.64(d, J=6.7Hz, 2H), 1.69-1.82(m, 1H), 2.90-3.10( m, 1H), 3.16-3.37(m, 1H), 3.50-3.61(m, 1H), 3.70-4.00(m, 1H), 4.23(s, 2H), 4.48-4.63(m, 1H), 5.09(q, J=6.7Hz, 0.6H), 5.24(q, J=6.7Hz, 0.4H). 6.85-7.05(m, 2H), 7.15-7.23(m, 1H), 7.36(d, J=8.0Hz, 2H). Analysis SFC t R 3.793 min (PHENOMENEX® LUX® Cellulose-2 column, 4.6x150 mm, 20% IPA / CO2, 5 mL / min, 225 nm).
[0108] Human D1 receptor PAM assay The PAM activity of the compounds of the invention may be measured essentially as described in Svensson et al., An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-in Mices without Casusing Stereotypy or Tachyphylaxis. J. Pharmacol. Exp. Ther. (2017) 360:117-128.
[0109] More specifically, HEK293 cells stably expressing the human D1 receptor (accession number NM_000794) were generated by transfection using the pBABE-bleo retroviral vector and selected with Zeocin™ (InvivoGen). At approximately 80% confluency, cells were harvested using TrypLE™ Express (Gibco), suspended in FBS plus 8% DMSO, and stored in liquid nitrogen. On the day of the assay, cells were thawed and resuspended in STIM buffer (Hank's balanced salt solution supplemented with 0.1% BSA, 20 mM HEPES, 500 μM IBMX, and 100 μM ascorbic acid).
[0110] Test compounds are serially diluted (1:2) in DMSO into assay plates (ProxiPlate-384Plus, PerkinElmer) using acoustic dispensing (Labcyte) to provide 20 concentrations for a full response curve. 5 μL of STIM buffer containing 2000 cells and EC 20 Add test compound (80 nL) to 5 μL of 2X concentrated dopamine solution in STIM buffer that produces a level response (24 nM in stock solution, or 12 nM final), the final concentration of DMSO in the well is 0.8%. Incubate the plate at room temperature for a total reaction time of 60 minutes.
[0111] cAMP production is quantified using HTRF® detection (Cisbio) according to the manufacturer's instructions. Typically, lysis buffer containing anti-cAMP cryptate (5 μL) and D2 conjugate (from the HTRF® kit) (5 μL) is added to the wells, the plate is incubated for a further 60-90 min, and time-resolved fluorescence is detected using an EnVision™ plate reader (PerkinElmer). Fluorescence data are converted to cAMP concentrations using a cAMP standard curve and analyzed using a four-parameter nonlinear logistic equation (Genedata Screener, version 13.0.5 standard). For concentration-response curves in potentiator mode, results are expressed as the EC 20The results are expressed as a percentage of the window between the response at a concentration (normalized to 0%) and the maximal response to dopamine (defined by the response to 5 μM dopamine, final concentration, normalized to 100%). Absolute EC 50 Values are calculated based on the maximum and minimum responses of the control agonist (dopamine). % potentiation (upper %) is determined from the fitted upper part of the concentration response curve. Absolute EC for specific example compounds 50 The top percentages are shown in Table 1 below. [Table 1-1] [Table 1-2]
[0112] The absolute EC values provided for the above example compounds in Table 1 50 The values illustrate the enhancement of human D1 receptor signaling in response to dopamine, illustrating the activity of the compounds of claim 1 as positive allosteric modulators of the human dopamine D1 receptor. Example compounds 1-6, and 8-11 of the present invention represent chiral compounds and were made and tested as individual stereoisomers as described in the Examples herein. See Examples 1-6, 8-11 and Table 1 above. Abs EC values in the range of 5.6 nM to 86.7 nM for the individual stereoisomers (Examples 1-6, 8-11) were 0.01 to 0.05 nM. 50) demonstrate that each individual stereoisomer represents a D1 positive allosteric modulator embodiment of the present invention. Characterization and determination of the absolute stereochemistry of the individual stereoisomers of the examples provided herein is within the skill of one of ordinary skill in the art, and methods for such determination are well known in the medicinal chemistry literature (see, for example, Chiral Analysis (Second Edition) Advances in Spectroscopy, Chromatography and Emerging Methods, 2018). For example, absolute configurations are generally determined by NMR based on the use of CDA: diastereomeric derivatives containing a covalent bond between the chiral auxiliary and the enantiomeric substrate adopt preferred conformations that can be predicted based on the differential shielding caused by the aromatic rings incorporated in the chiral discrimination reagent.
[0113] Generation of human D1 receptor knock-in mice Transgenic mice in which the mouse dopamine 1 (D1) receptor is replaced with its human counterpart can be generated by standard techniques (see generally Svensson et al., J. Pharmacol. Exp. Ther. (2017) 360:117-128). For example, mouse genomic fragments are subcloned from an RP23 bacterial artificial chromosome library and recloned into a PGK neo-targeting vector. The mouse open reading frame is replaced with the human D1 receptor open reading frame in exon 2. A neo-selectable marker upstream of exon 2 is flanked by frt sites for later removal. Flanking exon 2 by loxP selection sites allows the option of generating D1 knockout mice by breeding with mice expressing the cre nuclease gene.
[0114] The C57BL / 6N embryonic stem cell line B6-3 was cultured in 20% FBS and 2x10 6The cells are grown on a mitotically inactivated feeder layer of mouse embryonic fibroblasts in high glucose DMEM with 1000 units / l of leukemia inhibitory factor. Ten million embryonic stem cells and 30 micrograms of linearized vector DNA are electroporated and subjected to G418 selection (200 μg / ml). Clones are isolated and analyzed by Southern blotting.
[0115] Clones containing inserts of the expected size are inserted into blastocysts and the resulting mice are genotyped by PCR. Male chimeras are bred with females containing the flp nuclease gene to eliminate the selection marker. Offspring containing the human D1 receptor without the selection marker are identified by PCR. Male heterozygotes are bred with female C57BL / 6 mice. Male and female offspring containing the human D1 receptor are bred and homozygotes are identified by PCR. Behavior and reproduction of homozygotes are found to be normal and the colony is maintained in the homozygous state for subsequent generations.
[0116] Basic (habitual) locomotor activities The in vivo efficacy of the compound can be demonstrated to act through D1 receptors using the locomotor activity of mice. The locomotor activity is measured using an automated system that tracks mouse movement. The locomotor activity behavior of mice is monitored in a transparent plastic shoebox cage with dimensions of 45×25×20 cm, which is covered with a plastic cage top with ventilation filter and has a 1 cm depth of wood chips for absorbent bedding. To detect body movement (locomotion), the cage is placed in a rectangular frame containing a grid of 12 photocell beams in an 8×4 configuration (Kinder Scientific, Poway, CA) that are placed 2.5 cm above the cage floor and recorded by computer.
[0117] Male human D1 receptor knock-in mice are placed in the chamber and allowed to acclimate to the chamber for 60 minutes.During the acclimatization period, mice show a decrease in spontaneous locomotion over time, as expected.After administration of the compound of the present invention, the movement of animals is found to increase in a dose-dependent manner.
[0118] Mice are randomly assigned to treatment groups. For dose-response studies, each mouse is individually placed into one of the locomotor activity boxes for a 60-minute habituation period. Mice are then orally dosed with test compound in 20% hydroxypropyl-beta cyclodextrin vehicle and at a dose of 10 mL / kg. After dosing, mice are placed back into the LMA box and the total number of locomotion movements is recorded for each mouse at each 10-minute interval during the 60-minute measurement period. Statistical analysis is performed using one-way ANOVA, followed by post-hoc analysis using Dunnett's comparison test.
[0119] The compound of Example 7 is assayed essentially as described above and is found to increase basal locomotion in a dose-dependent manner (Table 2 below). [Table 2]
[0120] The basal locomotor activity data of Example 7 shown in Table 2 illustrates that the compounds of the present invention, particularly Example 7, are effective in locomotor activation of habituated animals. This activity is believed to be the result of central activation of D1 receptors via allosteric enhancement (see, e.g., Svensson et al., J. Pharmacol. Exp. Ther. (2017) 360:117-128). The data provided in Table 2 for Example 7 illustrates the pharmacologically advantageous in vivo potency of the compounds of the present invention for enhancing endogenous dopamine-mediated responses. The data provided in Table 2 for Example 7 further illustrates the pharmacologically advantageous oral bioavailability of Example 7 and the compound of formula I.
[0121] Plasma and brain levels: Example 7, 2-(2-chloro-6-fluoro-phenyl)-1-[(1S,3R)-6-fluoro-3-(hydroxymethyl)-5-(3-hydroxy-3-methyl-butyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone was orally administered to male mice at 3 mg / kg to 60 mg / kg in a fed state, and plasma and brain concentrations were determined 1 hour after administration. The unbound fraction of the compound was determined in vitro as previously described (Zamek-Gliszczynski MJ, et al., Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs., J.Pharm.Sci.(2011)100:2498-2507). The ratio (Kpuu) of unbound brain concentration (Cu, brain) to unbound plasma concentration (Cu, plasma) was determined as previously described (Raub TJ, et al., Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. Drug Metab. Dispos. (2015) 43:1360-71). The data presented below in Table 3 for Example 7 are the average from three animals at each dose. "Concentration (Con.)" refers to concentration. [Table 3]
[0122] The compounds of the present invention, such as Example 7, 2-(2-chloro-6-fluoro-phenyl)-1-[(1S,3R)-6-fluoro-3-(hydroxymethyl)-5-(3-hydroxy-3-methyl-butyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethenone, show an advantageous combination of pharmacological properties, such as enhancing human D1 receptor signaling in response to dopamine, high oral in vivo availability, central nervous system availability and in vivo efficacy in locomotor activation of habituated animals.For example, Example 7 demonstrates the enhancement of human D1 receptor signaling in response to dopamine (10.2±1.40 nM (n=15)) and significant in vivo efficacy in locomotor activation of habituated human D1 receptor knock-in mice when orally administered at 10, 30 and 60 mg / kg PO, illustrating the favorable oral bioavailability of this compound. Moreover, Example 7 is generally well tolerated when administered in vivo to normal rats over a wide dose range and shows an advantageous lack of toxicity in this in vivo experiment. Thus, Example 7 demonstrates an advantageous combination of favorable pharmacological properties that support its potential use as an orally administered therapeutic agent for dopamine D1 receptor enhancement and the treatment of Parkinson's disease, schizophrenia, ADHD, and / or Alzheimer's disease.
[0123] CYP3A4(fm CYP3A4 ) Determination of the fraction of a compound eliminated through metabolism The fraction of a drug's overall clearance via oxidative metabolism by cytochrome P450 (CYP) is an important indicator of potential victim drug interaction mediated adverse effects. (See generally Ogu, Chris C., and Maxa, Jan L., Drug interactions due to cytochrome P450, BUMC Proceedings 2000;13:421-423.) In particular, the greater the fraction of overall clearance for a given drug through the CYP oxidative pathway, e.g., through only a single CYP, e.g., CYP3A4, the greater the likelihood that the drug, when used in therapy, may prove susceptible to undesirable victim drug interactions. CYP3A4 To determine the fraction of metabolism mediated by CYP3A4, the fraction of P450-mediated oxidation (fm CYP ) is first determined in human hepatocytes. Recombinant CYP phenotyping assay (RCP) is then used to determine the CYP3A4-mediated oxidation (fm) relative to other P450s. CYP3A4_RCP Determine the relative contribution of fm CYP3A4 is calculated using the following formula:
number
[0124] Fraction (fm) of cytochrome P450 (CYP)-mediated oxidative metabolism in human hepatocytes CYP ) Determination The relative contribution of P450s in the overall metabolism of a compound was determined from the clearance of the drug in an assay using human hepatocytes in the presence and absence of the pan P450 inhibitor 1-aminobenzotriazole (ABT). Intrinsic clearance was determined in cryopreserved human hepatocytes essentially as described in McGinnity DF, et al. (2004) Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 32:1247-1253. Generally, assay incubations consisted of 0.3 μM test compound and 10 μM DMSO with or without a 0.5-h preincubation with ABT (1 mM). 6 cells / mL of hepatocytes. Parent compound loss is measured by LC / MS after 15, 30, 60, and 90 min of incubation. Intrinsic clearance (μL / min / 10 6 The inhibition by CYP (cells) is calculated for both ±ABT using the following formula: The fraction metabolized by CYP is the percentage of inhibition by ABT.
number
[0125] Fraction of CYP3A4-mediated metabolism (fm CYP3A4_RCP ) Determination The relative fraction of a compound's metabolism contributed by a given CYP, such as CYP3A4, of the compound's total P450 metabolism can be determined as follows.
[0126] A panel of nine human recombinant CYPs (rCYPs) provided as Supersomes (BD Gentest, Woburn, MA), including rCYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2J2, 3A4, and 3A5, are evaluated for compound metabolism (see generally, Cannady EA, et al. (2015) Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors. Pharmacol Res Perspect 3:e00179). Incubations and calculations are essentially as described in Wickremsinhe ER, et al. (2014), Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and / or metastatic solid tumors. Xenobiotica 44:827-841, except that incubations are performed for 2 hours due to the low turnover rate of the test compound. Intrinsic clearance (CL) in rCYP is measured. int ) is scaled to human liver microsomes according to the following formula (HLM scaled CL int ).
number
[0127] Fraction of CYP3A4-mediated metabolism (fm CYP3A4_RCP ) is the HLM scale CL of CYP3A4 int HLM-scale CL for each P450 subtype assayed int It is determined by dividing by the sum of (Cannady et al., 2015).
[0128] Hepatocyte metabolic profile The hepatocyte metabolic profile is measured to confirm the formation of metabolites via P450-mediated oxidative and phase II enzyme (e.g., UDP-glucuronosyltransferase and sulfotransferase)-mediated nonoxidative pathways. It is determined in human hepatocytes essentially as described in Zhou X, et al. (2016), Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats. Drug Metab Dispos 44:1184-1192). Briefly, incubation is performed in a CO2 incubator at 37°C using a 24-well plate containing 250,000 cells / well. Stock solutions of test compounds are added to the medium to result in a final incubation concentration of 2 μM. The incubation with medium and cells is quenched with an equal volume of acetonitrile after 4 hours. Samples are processed and analyzed using LC / MS essentially as described in Zhou et al. 2016.
[0129] The fraction of the compound eliminated through CYP3A4 metabolism (fm CYP3A4 ) calculation Renal and biliary excretion of test compounds are tested in bile duct cannulated dogs essentially according to Burkey JL, et al. (2002) Disposition of LY333531, a selective protein kinase C beta inhibitor, in the Fischer 344 rat and beagle dog. Xenobiotica 32:1045-1052. The compound of Example 7 is tested essentially as described, and its renal and biliary excretion is found to be negligible. The fraction of the compound eliminated through CYP3A4 metabolism is calculated using the following formula:
number
[0130] Fraction that escapes first-pass intestinal metabolism (F G ) Determination An estimate of the fraction metabolized in the intestine can be determined using the following formula found in Yang J, et al. (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684.
number
number
number
number
[0131] Human intestinal parameters are from Yang et al., 2007, and Gertz M, et al. (2010) Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147-1158.
[0132] A mechanistic static model for the estimation of casualty DDIs due to CYP3A4 inhibition Potential changes in drug AUC exposure of test compounds in the presence of itraconazole can be determined using a mechanistic static model essentially as described in Han B, et al. (2013) Prediction of CYP3A Mediated Drug-Drug Interactions: Estimation of Gut Wall and Hepatic Contributions. ASCPT Annual Meeting, Indianapolis, IN.
number
number
number
[0133] The parameters of itraconazole as a CYP3A4 inhibitor (A=0.10 and X=0.10) are according to Olkkola KT, et al. (1994) and midazolam should be avoided in patients receiving the systemic antifungal drugs ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485.
[0134] The compound of Example 7, which is representative of the compounds of intervention, was tested essentially as described above and found to be primarily metabolized through non-oxidative processes in hepatocytes, as opposed to oxidative metabolism by P450 (the fraction metabolized by CYP is 32.3%). The compound was not tested in an RCP assay, but a worst-case scenario of 100% metabolism by CYP3A4 was assumed to predict the AUC ratio in the presence of intraconazole. The predicted AUC ratio was less than 2. Thus, the compounds of the present invention are believed to exhibit minimal victim drug-drug interaction risk through any CYP, including CYP3A4 (see Table 4). [Table 4]
Claims
1. A compound of the formula: [Formula 1] During the ceremony, R 1 but, [chemical 2] and R 2 is -F or -Cl, R 3 is -F or -Cl, R 4 is -H or -F, However, R 1 but [C3] When R4 is -F.
2. A compound of the formula: [C4] During the ceremony, R 1 but, [C5] and R 2 is -F or -Cl, R 3 is -F or -Cl, R 4 is -H or -F, However, R 1 but [C6] 2. The compound of claim 1, wherein R4 is -F when
3. [C7] 2. The compound of claim 1,
4. A pharmaceutical composition comprising a compound according to any one of claims 1 to 3 and a pharma- ceutically acceptable carrier, diluent or excipient.
5. [C8] The pharmaceutical composition of claim 4, comprising a pharma- ceutically acceptable carrier, diluent, or excipient.
6. A pharmaceutical agent comprising a compound according to any one of claims 1 to 3 for the treatment of Parkinson's disease.
7. A pharmaceutical agent comprising a compound according to any one of claims 1 to 3 for the treatment of Alzheimer's disease.
8. Use of a compound according to any one of claims 1 to 3 for the manufacture of a medicament for the treatment of Parkinson's disease or Alzheimer's disease.
9. 1. A medicament for treating Parkinson's disease, comprising the compound 2-(2-chloro-6-fluoro-phenyl)-1-[(1S,3R)-6-fluoro-3-(hydroxymethyl)-5-(3-hydroxy-3-methyl-butyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone.
10. 1. A pharmaceutical for treating Alzheimer's disease, comprising the compound 2-(2-chloro-6-fluoro-phenyl)-1-[(1S,3R)-6-fluoro-3-(hydroxymethyl)-5-(3-hydroxy-3-methyl-butyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone.
11. 1. A medicament for treating a dopaminergic CNS disorder, comprising the compound 2-(2-chloro-6-fluoro-phenyl)-1-[(1S,3R)-6-fluoro-3-(hydroxymethyl)-5-(3-hydroxy-3-methyl-butyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone.
12. A pharmaceutical product comprising a compound according to any one of claims 1 to 3 for use in simultaneous, separate or sequential combination with a dopamine precursor in the treatment of a dopaminergic CNS disorder in a patient.
13. A pharmaceutical product comprising a compound according to any one of claims 1 to 3 for use in simultaneous, separate or sequential combination with a dopamine agonist in the treatment of a dopaminergic CNS disorder in a patient.
Citation Information
Patent Citations
3,4-dihydroisoquinolin-2(1h)-yl compounds
JP2016520127A
Tetrahydroisoquinoline derivative
JP2017530185A
Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators
WO2019204418A1
